The tissue-based test service helps identify and distinguish potentially aggressive cases of prostate cancer in men. Credit: MattL_Images / Shutterstock.com.

A partnership between Quest Diagnostics and Envision Sciences has introduced a new prostate cancer biomarker test.

Launched through Quest’s subspecialty pathology business AmeriPath, the tissue-based test service is designed to meet the critical clinical requirement for identifying and distinguishing potentially aggressive prostate cancer cases in men.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Quest created and validated the laboratory test through an intellectual property licence agreement with Envision.

This agreement enabled Quest to utilise Envision’s biomarker and immunohistochemistry technology, including staining technology and new biomarkers EV1, EV2 and EV3.

Recent pathology data demonstrated that when assessed with a panel based on three Envision biomarkers and technology, 22% of examined tissue specimens were upgraded while 20% were downgraded against the conventional assessment based on haematoxylin and eosin-stained tissue alone.

See Also:

Envision CEO Peter Pursey said: “Our patented technology provides a novel approach to visualising prostate cancer tissue and improving accuracy in grading cancer by pathologists.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We expect the test to enhance current prostate cancer histology practice and improve the information available to clinicians, enabling them to better align cancer grades with treatment options.”

In May this year, Quest Diagnostics announced the availability of a new risk assessment and care plan service across the US, known as RestoreU Dementia Panel.

RestoreU leverages artificial intelligence to make tailor-made care plans that intend to help physicians improve patient care and comply with cognitive care guidelines.